[go: up one dir, main page]

NI201000036A - Derivados de isoquinolinilo e isoindolinilo como antagonistas de histamina-3 - Google Patents

Derivados de isoquinolinilo e isoindolinilo como antagonistas de histamina-3

Info

Publication number
NI201000036A
NI201000036A NI201000036A NI201000036A NI201000036A NI 201000036 A NI201000036 A NI 201000036A NI 201000036 A NI201000036 A NI 201000036A NI 201000036 A NI201000036 A NI 201000036A NI 201000036 A NI201000036 A NI 201000036A
Authority
NI
Nicaragua
Prior art keywords
histamine
isoindolinyl
isoquinolinyl
antagonists
derivatives
Prior art date
Application number
NI201000036A
Other languages
English (en)
Inventor
Laird Gross Jonathan
Jean Robichaud Albert
Zhou Dahui
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of NI201000036A publication Critical patent/NI201000036A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

La presente invención proporciona un compuesto de fórmula I y su uso para el tratamiento de un trastorno del sistema nervioso central relacionado con, o que se ve afectado por el receptor histamina-3.
NI201000036A 2007-09-12 2010-03-11 Derivados de isoquinolinilo e isoindolinilo como antagonistas de histamina-3 NI201000036A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US99363607P 2007-09-12 2007-09-12

Publications (1)

Publication Number Publication Date
NI201000036A true NI201000036A (es) 2010-08-13

Family

ID=40261509

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201000036A NI201000036A (es) 2007-09-12 2010-03-11 Derivados de isoquinolinilo e isoindolinilo como antagonistas de histamina-3

Country Status (25)

Country Link
US (1) US20090069300A1 (es)
EP (1) EP2200989A1 (es)
JP (1) JP2010539180A (es)
KR (1) KR20100054856A (es)
CN (1) CN101848896A (es)
AP (1) AP2010005202A0 (es)
AR (1) AR068423A1 (es)
AU (1) AU2008298926A1 (es)
BR (1) BRPI0817061A2 (es)
CA (1) CA2699384A1 (es)
CL (1) CL2008002726A1 (es)
CO (1) CO6300955A2 (es)
CR (1) CR11303A (es)
DO (1) DOP2010000079A (es)
EA (1) EA201000316A1 (es)
EC (1) ECSP10010025A (es)
MA (1) MA31699B1 (es)
MX (1) MX2010002760A (es)
NI (1) NI201000036A (es)
PA (1) PA8795701A1 (es)
PE (1) PE20090651A1 (es)
TN (1) TN2010000105A1 (es)
TW (1) TW200927114A (es)
WO (1) WO2009036144A1 (es)
ZA (1) ZA201001751B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200823204A (en) * 2006-10-17 2008-06-01 Arena Pharm Inc Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine H3-receptor useful for the treatment of disorders related thereto
GB0907284D0 (en) 2009-04-28 2009-06-10 Queen Mary & Westfield College Compounds for inducing cellular apoptosis
CN102725290B (zh) * 2009-07-27 2016-03-09 吉利德科学股份有限公司 作为离子通道调节剂的稠合杂环化合物
NZ604478A (en) 2010-07-02 2014-12-24 Gilead Sciences Inc Fused heterocyclic compounds as ion channel modulators
WO2012058133A1 (en) * 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. Isoindolinone pde10 inhibitors
BR112013028886A2 (pt) * 2011-05-10 2016-08-09 Gilead Sciences Inc compostos heterocíclicos fundidos como moduladores dde canal de sódio
NO3175985T3 (es) 2011-07-01 2018-04-28
TW201837023A (zh) 2011-07-01 2018-10-16 美商基利科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
WO2013004652A1 (de) 2011-07-04 2013-01-10 Bayer Intellectual Property Gmbh Verwendung substituierter isochinolinone, isochinolindione, isochinolintrione und dihydroisochinolinone oder jeweils deren salze als wirkstoffe gegen abiotischen pflanzenstress
WO2013076590A1 (en) 2011-11-23 2013-05-30 Oxygen Healthcare Research Pvt. Ltd Benzothiazine compounds as h3 receptor ligands
CN105254554B (zh) * 2014-07-14 2018-01-30 南开大学 一种制备异吲哚啉酮类化合物的方法
MX2022012678A (es) * 2020-04-08 2023-01-11 Remix Therapeutics Inc Compuestos y metodos para modular el corte y empalme.
EP4203952A4 (en) * 2020-08-28 2024-12-11 Kumquat Biosciences Inc. HETEROCYCLIC COMPOUNDS AND USES THEREOF
CN115819347B (zh) * 2022-11-14 2024-08-30 暨明医药科技（苏州）有限公司 一种1-烷基-3-溴吡唑的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3933829A (en) * 1974-08-22 1976-01-20 John Wyeth & Brother Limited 4-Aminoquinoline derivatives
US4159331A (en) * 1978-05-05 1979-06-26 The Upjohn Company Antihypertensive 4-aminoquinolines
US4166853A (en) * 1978-05-05 1979-09-04 The Upjohn Company Antihypertensive 7-trifluoromethyl-4-aminoquinolones
IL117149A0 (en) * 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
CA2287984A1 (en) * 1997-05-01 1998-11-05 Gerald Floyd Smith Antithrombotic agents
EP1379493A2 (en) 2001-03-23 2004-01-14 Eli Lilly and Company Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses
UA80437C2 (en) * 2002-09-19 2007-09-25 Lilly Co Eli Diaryl ethers as opioid receptor antagonist
ES2299080T3 (es) * 2004-05-14 2008-05-16 Millennium Pharmaceuticals, Inc. Compuestos y metodos para inhibir la progresion mitotica mediante la inhibicion de quinasas aurora.
US20060014733A1 (en) * 2004-07-19 2006-01-19 Pfizer Inc Histamine-3 agonists and antagonists
US7381732B2 (en) * 2004-10-26 2008-06-03 Bristol-Myers Squibb Company Pyrazolobenzamides and derivatives as factor Xa inhibitors
MX2007008843A (es) * 2005-01-21 2007-08-22 Schering Corp Derivados de imidazol y bencimidazol utiles como antagonistas de histamina h3.
CA2604920A1 (en) * 2005-04-15 2006-10-26 Elan Pharmaceuticals, Inc. Novel compounds useful for bradykinin b1 receptor antagonism

Also Published As

Publication number Publication date
AR068423A1 (es) 2009-11-18
JP2010539180A (ja) 2010-12-16
ECSP10010025A (es) 2010-08-31
AU2008298926A1 (en) 2009-03-19
ZA201001751B (en) 2010-11-24
CL2008002726A1 (es) 2008-10-10
CO6300955A2 (es) 2011-07-21
CA2699384A1 (en) 2009-03-19
BRPI0817061A2 (pt) 2015-03-24
PE20090651A1 (es) 2009-05-28
PA8795701A1 (es) 2009-04-23
EP2200989A1 (en) 2010-06-30
AP2010005202A0 (en) 2010-04-30
EA201000316A1 (ru) 2010-10-29
CN101848896A (zh) 2010-09-29
US20090069300A1 (en) 2009-03-12
TN2010000105A1 (fr) 2011-09-26
KR20100054856A (ko) 2010-05-25
MA31699B1 (fr) 2010-09-01
DOP2010000079A (es) 2010-03-31
WO2009036144A1 (en) 2009-03-19
TW200927114A (en) 2009-07-01
MX2010002760A (es) 2010-04-01
CR11303A (es) 2010-03-18

Similar Documents

Publication Publication Date Title
NI201000036A (es) Derivados de isoquinolinilo e isoindolinilo como antagonistas de histamina-3
DOP2010000078A (es) Derivados de azaciclilisoquinolinona e-isoindolinona como antagonistas de la histamina-3
ECSP055535A (es) Derivados de 1-heterociclialquil-3-sulfonilazaindol o azaindol como ligandos de 5-hidroxitriptamina-6
CR10309A (es) "compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1"
BRPI0907382B8 (pt) antagonista de receptor de opioide seletivo capa, seu uso e composição farmacêutica que o compreende
GT200500185A (es) Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
UY33379A (es) Compuestos de morfolina
CL2012000921A1 (es) Compuestos derivados de espiropiperidina-metilbenciloxifenil, activadores del receptor rpg-40; composicion farmaceutica que los comprende; y uso del compuesto para tratar diabetes.
UY32384A (es) Nuevas bencenosulfonamidas como bloqueadores de canales de calcio
ECSP055536A (es) Derivados de 1-heterociclilalquil-3-sulfonilindol o indazol como ligandos de 5-hidroxitriptamina-6
PA8790101A1 (es) Derivados de aminoalquilazol como antagonistas de histamina-3
TW200800958A (en) N-substituted-azacyclylamines as histamine-3 antagonists
CO6341625A2 (es) Derivados de indol como agentes anticáncer
CO6260091A2 (es) Derivados de iminopiridina y su uso
CL2008002767A1 (es) Compuestos derivados de heterociclico triciclico; composicion farmaceutica; y su uso para el tratamiento de un trastorno mediado por serotonina tal como obesidad, esquizofrenia y disfuncion cognitiva.
SV2005002061A (es) Derivados de piridilo y su uso como antagonistas del receptor mglu5 ref. x-16538
ECSP11011473A (es) Antagonistas de ccr3 de arilsulfonamida 2, 5- disustituída
GT200600081A (es) Derivados de acetilenno
PA8781601A1 (es) " derivados de azaciclilbenzamida como antagonistas de histamina-3
ECSP088176A (es) Derivados de azinil-3-sulfonilindazol como ligandos de5-hidroxitriptamina-6
PA8814801A1 (es) Triazolopiridazinas como inhibidores de par1, su preparación y su uso como medicamentos
CR9734A (es) Derivados de 3-sulfonilindazol sustituido como ligandos de 5-hidroxitriptamina-6
BRPI0916657A2 (pt) pirrolidin-3-ilmetil-amina como antagonistas de orexina
GT200600422A (es) Derivados de carboxamida como antagonistas del receptor muscarinico
UY31646A1 (es) Uso de fenilimidazolidinas sustituidas para producir medicamentos para el tratamiento del síndrome metabólico